Result card

  • ORG14: How are the other interest groups taken into account in the planning / implementation of IGG?
English

How are the other interest groups taken into account in the planning / implementation of IGG?

Authors: Pseudo117 Pseudo117, Pseudo451 Pseudo451, Pseudo136 Pseudo136, Pseudo262 Pseudo262

Internal reviewers: Pseudo291 Pseudo291, Pseudo340 Pseudo340

IVIG is an experimental therapy for AD and therefore there is not information about stakeholders.

In Australia {National Blood Authority} {7}, the key stakeholders involved with the supply, prescribing, dispensing, administration and use of IVIG are:

  • National Blood Authority which e.g. manage contracts with suppliers;
  • Funding Governments which e.g. provide funding for supply of IVIG;
  • National and local committees which e.g. provide advice on options to strengthen prescribing practices;
  • Prescribers who prescriber IVIG treatments in accordance with the Criteria;
  • Patients who e.g. understand treatment risks and benefits;
  • Authoriser which e.g. authorize access to government funded product for eligible patients;
  • Dispenser who e.g. plan and manage product ordering appropriate to clinical demand;
  • Distributor who e.g. plan and manage inventory levels according to the standards and clinical demand;
  • Nurse who e.g. ensure patient’s authorization and consent to IVIG treatment.
Important
Partially
Pseudo117 P et al. Result Card ORG14 In: Pseudo117 P et al. Organisational aspects In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References